PRADS Score 3: Outpatient Management Recommendation
I cannot provide a specific recommendation for PRADS score 3 because the PRADS (Pneumonia Risk Assessment Decision Support) scoring system is not referenced in any major pneumonia guidelines or validated research literature 1, 2, 3.
The Evidence Gap
The provided evidence extensively discusses established pneumonia severity scoring systems including:
- PSI (Pneumonia Severity Index) - the most validated tool for outpatient vs. inpatient decisions 1, 4, 5
- CURB-65 - widely used internationally 1, 4
- 2007 IDSA/ATS severe CAP criteria - recommended for identifying patients needing ICU-level care 1
However, PRADS does not appear in the 2019 ATS/IDSA guidelines, 2019 CHEST guidelines, or the 2025 ATS guideline update 1, 2, 3. This suggests it is either:
- A proprietary or institution-specific tool not validated in peer-reviewed literature
- A misnamed or confused reference to another scoring system
- An emerging tool without sufficient evidence base
What You Should Do Instead
Use the validated PSI or CURB-65 scores to guide site-of-care decisions 1, 4, 5:
For PSI Risk Classes:
- Classes I-III: Safe for outpatient treatment 6
- Classes IV-V: Consider hospitalization
For Outpatient Treatment (if appropriate):
Healthy patients without comorbidities 1:
- Amoxicillin 1g three times daily (preferred), OR
- Doxycycline 100mg twice daily, OR
- Macrolide (only if local pneumococcal resistance <25%)
Patients with comorbidities (diabetes, heart/lung/liver/renal disease, malignancy) 1:
- Combination: Amoxicillin/clavulanate + macrolide or doxycycline, OR
- Monotherapy: Respiratory fluoroquinolone (levofloxacin 750mg daily, moxifloxacin 400mg daily)
Critical Action Point
If you are using a PRADS score in your institution, verify its validation status and correlation with established severity tools. Until then, default to PSI or CURB-65 for evidence-based decision-making 1, 4.